Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Work
Year: 2021
Type: article
Abstract: Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter ... more
Source: Annals of Oncology
Authors Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat +18 more
Institutions Massachusetts General Hospital, Harvard University, University of Colorado Denver, University of Colorado Cancer Center, Goshen Health +19 more
Cites: 36
Cited by: 239
Related to: 10
FWCI: 22.01
Citation percentile (by year/subfield): 100
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $4,060